What happened?
The CHMP issued a positive opinion on 15 October 2026 recommending marketing authorisation for Foundayo (active substance orforglipron), an oral GLP‑1 receptor agonist. The EMA summary cites clinically relevant improvements in glycaemic control and additional weight loss benefits when combined with diet and physical activity. Common adverse effects were gastrointestinal (nausea, vomiting, diarrhoea).
Why does it matter?
An oral GLP‑1 agent with dual indications could broaden treatment options for adults with type 2 diabetes and for weight management in people with obesity or overweight plus comorbidity. The opinion recognises both glycaemic and weight effects, potentially affecting clinical choices if authorised and accessible locally.
How to interpret the evidence
The CHMP opinion is based on submitted trial data; full study details and subgroup results are in the product documentation. The opinion still requires European Commission authorisation and national decisions for Malta/EU supply and reimbursement. Clinical use will depend on SmPC details and local availability, not automatic access.
What remains uncertain?
This opinion is not an immediate EU marketing authorisation, nor does it imply availability in Malta. It does not mean Foundayo replaces metformin as first‑line therapy, nor does it by itself establish cardiovascular outcome benefit; see formal SmPC and published trial reports for specifics.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.
This summary was prepared with AI assistance and checked automatically against the linked primary source. It has not been individually reviewed by a clinician.